Infiniwell BPC-157 FAQ

A synthetic 15-residue pentadecapeptide derived from a gastric-juice protein sequence. Proposed mechanisms include pro-angiogenic activity at injury sites, modulation of growth-factor and VEGF-related signaling, and interaction with the nitric oxide pathway. None is established in controlled human trials; the evidence base is predominantly rodent and predominantly parenteral.

A single active: 500 mcg of synthetic BPC-157 in a vegetarian shell, without a proprietary blend. Dose transparency is a point in its favor. Confirm the figure against the current label.

It is the central interpretive issue. The preclinical outcomes used subcutaneous or intraperitoneal administration; an oral capsule cannot be assumed to reproduce them. The defensible reading is meaningful local enteral activity consistent with the peptide's gastric origin, plus uncertain systemic exposure — which makes the musculoskeletal indication the least supported.

Labels suggest one to two capsules daily. For an enteral target, one capsule on an empty stomach, roughly 20 to 30 minutes before food; for a musculoskeletal target, two daily on a relatively empty stomach. It should be co-prescribed with progressive loading rather than used as a standalone intervention.

A bounded four-to-six-week cycle with a two-week washout, tied to defined pre- and post-assessment, not indefinite maintenance — justified by the absence of long-term human data, the unsettled regulatory status, and the inadvisability of sustained pro-angiogenic exposure without monitoring.

Active or recent malignancy (pro-angiogenic mechanism) and pregnancy or lactation (no data) are firm. Immunosuppressive therapy requires prescriber coordination. High-dose NSAIDs and systemic corticosteroids are mechanistically opposed and should not be co-administered.

Not FDA-approved and not a DSHEA dietary supplement. The status is evolving: BPC-157 came off the FDA Category 2 list in April 2026 and is under review for the 503A bulk-substances compounding list in July 2026. Legitimate access is via the practitioner channel for the oral form and physicians plus compounding pharmacies for the injectable.

Specificity of target and rehabilitation adherence. Patients with a discrete objective who maintain progressive loading are the ones who report benefit; undifferentiated 'global recovery' use rarely produces a discernible result.